These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 39422953)

  • 1. Amyloid-Directed Antibodies: Past, Present, and Future.
    Noorda K; Noorda K; Sabbagh MN; Bertelson J; Singer J; Decourt B
    J Alzheimers Dis; 2024; 101(s1):S3-S22. PubMed ID: 39422953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
    Suzuki N; Hatta T; Ito M; Kusakabe KI
    Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
    Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
    Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
    Jin M; Noble JM
    eNeuro; 2024 Sep; 11(9):. PubMed ID: 39332901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
    Song T; Wang Y; Silverglate BD; Grossberg GT
    Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive immunotherapy for Alzheimer's disease: challenges & future directions.
    Yi LX; Tan EK; Zhou ZD
    J Transl Med; 2024 May; 22(1):430. PubMed ID: 38715084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive immunotherapy for Alzheimer's disease.
    Guo X; Yan L; Zhang D; Zhao Y
    Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.
    Lian Y; Jia YJ; Wong J; Zhou XF; Song W; Guo J; Masters CL; Wang YJ
    Mol Psychiatry; 2024 Feb; 29(2):297-305. PubMed ID: 38001337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders.
    Lasheen NN; Allam S; Elgarawany A; Aswa DW; Mansour R; Farouk Z
    J Physiol Sci; 2024 Sep; 74(1):46. PubMed ID: 39313800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.
    Vander Zanden CM; Chi EY
    J Pharm Sci; 2020 Jan; 109(1):68-73. PubMed ID: 31647950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
    Fedele E
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.